Skip to main content
Rekvina Laboratories Ltd logo

Rekvina Laboratories Ltd — Investor Relations & Filings

Ticker · 526075 ISIN · INE092O01028 BSE.NS Manufacturing
Open in API
Filings indexed 3 across all filing types
Latest filing 2026-05-21 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS 526075

About Rekvina Laboratories Ltd

https://www.rekvinalaboratories.com

Rekvina Laboratories Ltd is a pharmaceutical manufacturing company focused on the development and production of a wide range of medicinal formulations. The company's product portfolio includes tablets, capsules, liquid orals, ointments, and dry syrups across various therapeutic segments such as anti-infectives, analgesics, anti-inflammatory agents, and gastrointestinal treatments. Operating with WHO-GMP certified facilities, the organization emphasizes quality control and adherence to international manufacturing standards. The company provides contract manufacturing services and branded generic products to healthcare providers and distributors, maintaining a focus on therapeutic efficacy and regulatory compliance.

Recent filings

Filing Released Lang Actions
Standalone Audited Financial Results for the Quarter ended & Year ended on March 31, 2026 along with statement of Assets & Liabilities, Cash Flow statement & unmodified Audit Report.
Interim / Quarterly Report Classification · 95% confidence The document is the formal outcome of the Board Meeting under Regulation 33 of SEBI LODR. It includes complete standalone audited financial results for the quarter and full year ended 31 March 2026, with detailed P&L, Balance Sheet, Cash Flow statements, notes, and the Independent Auditor’s Report. It is too detailed to be an earnings release or just an announcement, and it consists of actual financial statements for a period shorter than a full fiscal year (the quarter) with audit opinions. Therefore, it falls under Interim / Quarterly Report (IR). FY 2026
2026-05-21 English
Pursuant to Reg 33 read with Part A of Schedule III of SEBI (LODR) Regulation, 2015, we hereby submitting the following: 1. Standalone Audited Financial Results for the Quarter ended ....
Interim / Quarterly Report Classification · 89% confidence The document is the formal outcome of the Board meeting under SEBI LODR Regulation 30 and 33, containing the full standalone audited financial results for the quarter and year ended March 31, 2026 (P&L, Balance Sheet, Cash Flow) plus the Independent Auditor’s Report. It is not an “Annual Report” with MD&A or governance sections, but rather the company’s audited periodic financial statements. Under our taxonomy, this fits as an Interim/Quarterly Report (IR) filing of quarterly (and year‐end) financial results. FY 2026
2026-05-21 English
Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve Financial Result for the ....
Regulatory Filings Classification · 82% confidence The document is a notice to the stock exchange pursuant to SEBI LODR Regulation 29 informing of a Board meeting date and trading window closure. It does not contain financial results, changes in board/management, or actual report content—it is a regulatory announcement. Therefore, it fits the general Regulatory Filings category (RNS).
2026-05-18 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.